This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain in back and/or lower extremities were associated with greater improvements ...

A $2.5 million federal grant will fund a four-year study led by Kessler Foundation scientist Karen J. Nolan, PhD, to explore ...

Philadelphia-based Rothman Orthopaedic Institute has been at the forefront of spine care, and recently a team partnered with Thomas Jefferson University Hospita ...

Researchers at Kennedy Krieger Institute's International Center for Spinal Cord Injury (ICSCI) have made a remarkable ...

Realizing a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury. Since the passing of ...

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

A team of researchers led by Rice University's Jacob Robinson and the University of Texas Medical Branch's Peter Kan has ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...